Radotinib(IY-5511) CAS:926037-48-1

Radotinib is a selective second generation tyrosine kinase inhibitor that targets both the wild-type and mutant forms of Bcr-Abl,with an IC50 value of 30.6 nM in Ba/F3 human chronic myeloid leukemia cells expressing the wild-type form.Radotinib also inhibits platelet-derived growth factor receptors(PDGFRs)α and β with IC50 values of 75.5 and 130 nM,respectively.Binding of radotinib to Bcr-Abl in vitro inhibits the phosphorylation of the downstream signaling mediator CrkL.3 In acute myeloid leukemia cells,in vitro treatment with radotinib at doses of 10-100 µM reduces viability,activates the mitochondrial apoptosis pathway,and promotes expression of the differentiation marker CD11b.

msds---Radotinib(IY-5511)